Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2026—In the cat-and-mouse maneuverings that often propel new cancer treatments, menin inhibitors are proving to be successful epigenetic therapies for acute leukemia. Last November brought FDA approval of revumenib for treatment of adults and children (one year and older) with relapsed or refractory acute myeloid leukemia with NPM1 gene mutations.
June 2026—Despite elevated Lp(a) concentration having a high population prevalence of about 20 percent, the testing rate has been low, and that is about to change.
June 2026—The immunostaining landscape for lung neuroendocrine tumors continues to evolve, and Humberto Trejo Bittar, MD, in a CAP25 lung cancer session last fall, captured where it stands.
June 2026—Alternative revenue models for laboratories, specifically laboratory testing for functional health and other health care practices that traditionally haven’t been part of conventional medicine, came up in a May 6 online Compass Group roundtable, led by CAP TODAY publisher Bob McGonnagle.
June 2026—The primary reason for health insurance is to help patients pay for medical care when they need it. Beneficiaries pay their premiums when healthy to receive payouts when sick. Sounds simple, and at its inception it was. Dallas, Tex., gave birth in 1929 to the precursor of the Blue Cross system. Plan members paid in, and if hospitalization was needed, care was rendered and fees were paid by the community pool. But we’ve come a long way since then.
June 2026—We present the case of a 75-year-old woman with a history of a pT4 colorectal adenocarcinoma who was status-post right hemicolectomy two years prior to the current care episode. She returned for urgent medical evaluation of recurrent abdominal pain, was diagnosed with a small bowel obstruction, and underwent exploratory laparotomy with small bowel resection and primary anastomosis.
June 2026—How and why gastric cancer scoring for HER2 positivity differs from breast cancer scoring was the topic of a CAP TODAY webinar early this year presented by Josef Rüschoff, MD, of Kassel, Germany.
June 2026—Instrumentation for all laboratory testing sites—large and small—was the roundtable topic on April 21 when representatives of Roche, Beckman Coulter, and Siemens Healthineers met online with Moira Larsen, MD, MBA, of MedStar, and Joe Baker of Baylor Scott & White. CAP TODAY publisher Bob McGonnagle led, with questions about, among other things, AI, testing consolidation, what laboratories expect of vendors, and what laboratories are willing to contribute to the partnership. “We’re happy to help figure out what the bugs are,” Baker says of new instrumentation.
June 2026—CAP TODAY publisher Bob McGonnagle spoke on March 12 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Jesse M. Young, PhD, medical director for TriCore Research Institute’s research and clinical trials department and director of point-of-care testing. Dr. Young is also clinical assistant professor at the University of New Mexico.
Bob McGonnagle: Dr. Young, tell us about TriCore and the laboratories you oversee.
Dr. Young (TriCore): TriCore Reference Laboratory is a full-service diagnostic laboratory. The core laboratory offers about 2,900 test codes and has a modality similar to that of Labcorp and Quest, but we’re focused on New Mexican populations. We serve most of the hospitals in the area and have statewide collection sites whereby we’re trying to expand health care and provide coverage for our communities so everyone in the state has access to health care near their home instead of having to drive six hours to the nearest collection site, drive home, and then be called back for a critical value. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ZeptoMetrix.
June 2026—Serving on a CAP council or committee is a prestigious and valuable thing to do—but the path to getting there can seem almost impossible to navigate. In recent years, the CAP has changed the process to make it as transparent as possible and to give more people an opportunity to get involved. I’d like to shine a light on committee and council participation to help demystify one of the most important ways you can become more engaged with the CAP.
